The 2 events (grade 3 lymphopenia and grade 3 thrombocytopenia) occurring at the 20 μg dose level constituted dose-limiting toxicities (DLTs), and led to dose reduction of rHuIL-12 to 15 μg. This evidence concerns the gene SPRR2A and lymphopenia.